3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Neoplasms
2
Hemorrhage
2
Thrombocytopenia
1
Recurrence
1
Postoperative Hemorrhage
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Blood Loss, Surgical
1
Interventions
venetoclax
124
Azacitidine
96
Cytarabine
71
fludarabine
44
Specimen Handling
38
Cyclophosphamide
38
Daunorubicin
27
Decitabine
26
Biopsy
25
Idarubicin
24
Granulocyte Colony-Stimulating Factor
21
gilteritinib
18
Injections
18
fludarabine phosphate
17
Whole-Body Irradiation
17
Melphalan
16
Busulfan
16
Stem Cell Transplantation
15
Mycophenolic Acid
15
ivosidenib
13
Cladribine
13
decitabine and cedazuridine drug combination
12
Gemtuzumab
12
Tacrolimus
11
CPX-351
11
X-Rays
10
Filgrastim
10
revumenib
9
enasidenib
9
Cyclosporine
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia, Myeloid, Acute
×
Tranexamic Acid
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled